Nasdaq Correction Have You Worried? 3 Unstoppable Stocks to Buy Hand Over Fist Right Now.

The Nasdaq-100 is in a correction, down more than 10% from highs amid geopolitical concerns in Iran that could push oil prices and inflation higher. Oscar Health reports it began 2026 with 3.4M members and guides $250M–$450M in operating income for 2026 (market cap ~$3.3B), highlighting a path to profitability. Adyen: H2 revenue +21% y/y (constant currency) with ~55% EBITDA margins, shares off >50% from 12-month highs and trading at a P/E ~26. Remitly: latest quarter revenue $442M (+26% y/y) with a record 9% operating margin, market cap ~$3.1B and shares down ~69% from all-time highs.

Analysis

The market correction has amplified correlation risk and created idiosyncratic opportunity: enterprise payment processors and digital remitters benefit from secular volume shifts (cross-border e‑commerce and remittances) that are largely orthogonal to oil-driven inflation shocks. Those businesses have embedded operating leverage—small moves in take‑rate or processed volume flow straight to EBITDA because fixed tech costs dominate incremental cost—so a permanent re‑rating is plausible if growth stabilizes over 12–24 months.

Key second‑order dynamics work in favor of incumbents with deep integrations: merchant churn is expensive, so Adyen and similar platforms can widen spreads by bundling fraud tools, data services and cross‑border FX execution, squeezing smaller local processors. Conversely, Remitly’s path to scale is corridor‑dependent; adverse FX volatility, cash‑pickup franchise loss, or tighter AML/know‑your‑customer enforcement in a few large corridors could compress unit economics faster than headline volume growth suggests.

On the healthcare side, an insurance operator that must convert new members into profitable lifetime customers faces three levers—pricing, care management savings, and claims adjudication efficiency—that compound over multiple years. That makes a staged allocation with active monitoring of gross margin per member and medical loss ratio (MLR) the right playbook rather than a binary buy/avoid judgment.

Overall, the market appears to be pricing these secular stories as if macro shocks will permanently reduce end markets; a more measured view is that macro volatility is transitory and will amplify winners with durable product differentiation. Time horizons matter: expect asymmetry to resolve over 12–36 months, not days, and size positions accordingly.

Key Decisions for Investors

• Long ADYEY (Adyen OTC) — initiate a 12–24 month position sized 2–4% NAV via shares or LEAP calls (12–18 month). Rationale: 40%+ SaaS-like gross margins and stickier enterprise revenue should re-rate if take‑rates tick up 50–100bps; target 40–80% upside in 12–24 months, stop‑loss at 30% below entry.
• Long RELY (Remitly) — starter position 1.5–3% NAV via shares plus buy a 18–24 month LEAP to capture market share optionality. Hedge: buy a small out‑of‑the‑money 12 month put to protect vs EM FX shocks. Risk/reward: asymmetric 2x upside if corridor share gains continue, tail risk from regulatory/FX shocks could wipe 40–60%.
• Long OSCR (Oscar Health) — tactical 1–2% NAV core position; monetize near‑term volatility by selling 3–6 month covered calls (~25–35% OTM) to collect premium while monitoring monthly MLR and churn metrics. Expect 30–60% upside if operating margins normalize over 12 months; regulatory or subsidy news can compress value quickly so keep tight event stops.
• Hedge tech beta via short NDAQ (Nasdaq, exchange operator) puts or buy index put spread on Nasdaq‑100 equivalent — allocate 1–2% NAV as downside protection for 3–6 months. This preserves exposure to idiosyncratic winners while protecting portfolio against further indiscriminate index de‑risking; cost should be capped (use spreads) with payoff kicking in if another >8–12% index leg down occurs.